Bayesian Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bayesian Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,115	Closed	-$480K	–	606
2019 Q1	$480K	Sell	6,115 -3,206	-34%	-$243K	0.09%	300
2018 Q4	$789K	Buy	9,321 +2,350	+34%	+$251K	0.16%	200
2018 Q3	$1.19M	Buy	6,971 +4,980	+250%	+$751K	0.2%	139
2018 Q2	$257K	Buy	+1,991	New	+$222K	0.06%	446
2017 Q4	–	Sell	-6,733	Closed	-$572K	–	641
2017 Q3	$572K	Buy	+6,733	New	+$533K	0.14%	243

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bayesian Capital Management's LGND Position: Q2 2019 in Review

Bayesian Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 6,115 shares — an estimated $480K sold.

Bayesian Capital Management first reported a position in LGND in Q3 2017 and held it in 5 quarters. The position peaked at $1.19M in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Bayesian Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Bayesian Capital Management sold 6,115 Ligand Pharmaceuticals shares in Q2 2019, an estimated $480K.
Bayesian Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Bayesian Capital Management's Ligand Pharmaceuticals position peaked at $1.19M in Q3 2018.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Bayesian Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.